Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...

Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid ...

Tumor necrosis factor (TNF) inhibitors protect patients with axial spondyloarthritis (axSpA) from hip and spine fractures better than other drugs. Large US insurance claims database study comparing ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

Please provide your email address to receive an email when new articles are posted on . There were “no significant differences” in efficacy, safety or adherence for TNF inhibitors between young- and ...

Children with nonsystemic juvenile idiopathic arthritis who initiated TNF inhibitors when aged 2 years or less showed significant and sustained improvements in disease activity. Early initiation of ...

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

Though TNF inhibitor exposure during pregnancy and postpartum was not associated with a significantly increased risk for serious infection, exposed pregnancies had numerically higher rates. The ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...

“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease. A new study published recently in the journal Gut shows children with Crohn's who ...

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s ...